Summary Activating mutations in glutamate dehydrogenase (GDH), de novo or dominantly inherited, are responsible for the hyperinsulinism/hyperammonemia (HI/ HA) syndrome. Epilepsy has been frequently reported in association with mutations in GDH, but the epilepsy phenotype has not been clearly determined. Here, we describe a family with a dominantly inherited mutation in GDH. The mother, brother and both sisters had myoclonic absence seizures, but only the mother and one sister had the complete HI/HA pattern. For the two sisters with myoclonic absences, epilepsy started during the second year of life while the brother, it started at 6 years. All 3 children showed the same EEG pattern characterized by photosensitive generalized and irregular spike-wave discharges and runs of multiple spikes. The mother's EEG recordings were normal without photosensitivity. Magnetic resonance imaging (MRI)
KEYWORDS
Photosensitivity; Hyperinsulinism/ hyperammonemia syndrome; Glutamate dehydrogenase; Myoclonic absence Summary Activating mutations in glutamate dehydrogenase (GDH), de novo or dominantly inherited, are responsible for the hyperinsulinism/hyperammonemia (HI/ HA) syndrome. Epilepsy has been frequently reported in association with mutations in GDH, but the epilepsy phenotype has not been clearly determined. Here, we describe a family with a dominantly inherited mutation in GDH. The mother, brother and both sisters had myoclonic absence seizures, but only the mother and one sister had the complete HI/HA pattern. For the two sisters with myoclonic absences, epilepsy started during the second year of life while the brother, it started at 6 years. All 3 children showed the same EEG pattern characterized by photosensitive generalized and irregular spike-wave discharges and runs of multiple spikes. The mother's EEG recordings were normal without photosensitivity. Magnetic resonance imaging (MRI)
Introduction
Activating mutations in glutamate dehydrogenase (GDH) are de novo mutations that produce a heterogeneous phenotype with (HI/HA) syndrome. Epilepsy and mental retardation are frequently associated with mutations in GDH, but the epilepsy phenotype has not been clearly determined and the pathophysiological mechanisms are not yet understood. [1] [2] [3] [4] HI/HA syndrome is characterized by hyperinsulinemic hypoglycemia and hyperammonemia.
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and spectroscopy (MRS) were normal. A direct effect of the GDH mutation, perhaps in combination with recurrent hypoglycemia and chronic hyperammonemia could provide a pathophysiological explanation for the epilepsy observed in this syndrome and these are discussed. # 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved. Hypoglycemia related to HI/HA syndrome is usually less severe than hyperinsulinemic hypoglycemia secondary to an ion channel disorder, 5 with a good response to medical treatment, namely diazoxide and a protein restricted diet. 1, 6 Hyperammonemia, up to 3-5 times normal, is asymptomatic 1,2 and resistant to treatment.
GDH mutations result in a gain of enzyme function that leads to an increase of the oxidative deamination of glutamate to alpha-ketoglutarate and ammonia. This increased enzymatic reaction is responsible for increased Krebs cycle activity and b-cell ATP/ADP ratio. The latter activates the K ATP channel with subsequent cell depolarization and exaggerated insulin release. 7 Recently, Razen et al. reported the association of epilepsy with a gain of function mutation in GDH in 14 patients. 4 However, the clinical and electrophysiological features of this epilepsy were variable. Here, we describe a specific electroclinical pattern of three affected children from a family with dominantly transmitted GDH mutation. In an attempt to explore further the pathophysiological mechanisms underlying this epilepsy, we will provide biochemical and imaging data.
Family report
The proband (patient 1) is a girl referred to us at 11 months of age for hypoglycemic seizures. She was subsequently diagnosed with HI/HA syndrome, confirmed by the identification of a heterozygous activating GDH mutation in exon 6 in the GTP-binding site (833 C > T, pArg221Cys). 8, 9 We then discovered that her mother (patient 2), sister (patient 3) and brother (patient 4) carried the same mutation in GDH. One remaining brother was unaffected.
She was born at term and the pregnancy was uneventful. She presented at the age of 11 months with generalized tonic-clonic seizures associated with hypoglycemia. On admission, neurological examination was normal. Asymptomatic recurrent hypoglycemia was diagnosed with the lowest recorded glucose levels at 2 mmol/l. This was associated with hyperammonemia (100-120 mmol/l) with elevated glutamine levels (514 mmol/l, normal range <50 mmol/l). Despite frequent feeds and treatment with diazoxide, hypoglycemia persisted. At the age of 13 months, she underwent a subtotal pancreatectomy. After surgery, diazoxide was stopped. However, hypoglycemia recurred after surgery. This was well controlled by a protein restricted 660 N. Bahi-Buisson et al. diet. Her ammonia levels remained mildly elevated at 80-100 mmol/l, did not fall with fasting or rise with protein feeding and were independent of blood glucose levels. Interictal EEG recordings showed sleep-activated photosensitive spike-wave paroxysms.
Myoclonic absences started at the age of 24 months. They were characterized by repeated absence spells with eyelids myoclonia in association with massive and bilateral myoclonia. Her level of consciousness was impaired during the events but recovered immediately after. The events occurred more than 10 times per day. A 24 h EEG recording with close monitoring of blood glucose and ammonia levels, allowed us to record these episodes. They occurred either in isolation or in clusters of 2-3 and were associated with discharges of high amplitude and irregular generalized spikes (Fig. 1A) . They occurred both spontaneously and with photic stimulation (Fig. 1B) .
Treatment with clobazam reduced the frequency of myoclonic absences but did not abolish them. Carbamazepine transitorily worsened the seizures and was stopped. Levetiracetam in conjunction with clobazam led to a 50% reduction in seizure frequency.
Her mother (patient 2) presented with hypoglycemia during infancy, and this was well controlled by frequent feeding. She also had generalized seizures characterized by myoclonic absences with eyelid myoclonia and sometimes leading to falls. Theses seizures were controlled by sodium valproate until the age of 9 years. At the age of 40 years, she was seizure-free without medication. Glucose levels were normal; however, her ammonia was 80 mmol/l. Her EEG was normal.
The (Fig. 2) .
The elder brother (patient 4) presented with 3 episodes of myoclonic absences at the age of 6 years without hypoglycemia, but mild hyperammonemia was noted (90-110 mmol/l). No EEG was performed before the age of 11 years. EEG recordings later showed the same pattern of repeated and photo- sensitive discharges of spikes and polyspikes in clusters, sometimes associated with massive myoclonia (Fig. 3) .
In all the family, neuropsychological examination revealed moderate to severe mental retardation (respectively IQ 50 for patient 1, IQ 60 for patient 3, IQ 75 for patient 2 and 4).
MRI and MRS were performed all the 4 patients, and were normal. Cerebro-spinal fluid (CSF) aminoacid (glutamine) and CSF neurotransmitters (catecholamine and GABA) studies were normal. Biochemical results are summarized in Table 1 .
Discussion
Here, we report myoclonic absence epilepsy with photosensitivity in three children of a family with a dominantly inherited gain of function mutation in GDH. The seizure pattern was similar in the three children whereas the metabolic presentation varied from a typical HI/HA syndrome in the index case to isolated hyperammonemia in the sister and the brother. The mother also presented hypoglycemia followed by myoclonic absences during infancy and hyperammonemia which persisted in adulthood. The heterogeneity of the phenotype of HI/HA syndrome has been reported, 1, 10 but the epilepsy, which seems to be one of the main neurological symptom of the disease, remains to be more clearly defined.
Indeed, in a recent report, Raizen et al. described epilepsy in HI/HA patients but EEG and clinical data as well as the follow-up were too scarce to draw conclusions about the characteristics of the epilepsy. In light of this paper, the spectrum of epilepsy in HI/HA appear to be diverse, although the authors however did describe absences with eye or eyelid myoclonia in 2 siblings and another case 4 (additional table).
In our family, the epilepsy was clearly characterized by video-EEG recording which showed in both sisters photosensitive myoclonic absence seizures with generalized irregular spike and spike-wave discharges. Their seizures started at 2 years of age and were resistant to antiepileptic drugs, although levetiracetam slightly reduced their frequency.
Concerning epilepsy, we could observe a distinctive electroclinical phenotype that consists of photosensitive myoclonic absence seizures. These seizures recall the myoclonic absence like seizures occasionally observed in chromosome abnormalities and in succinic semialdehyde dehydrogenase (SSADH) deficiency. [11] [12] [13] They are characterized by the combination of atypical absence with a long duration of impairment of consciousness and myoclonic jerks involving the proximal muscles of the limbs particularly the deltoids. Falling or simple head nodding can occur in 50% of the cases described, and others seizures types, such as complex partial, tonic or clonic seizures can also be associated also in 50% of the cases. [11] [12] [13] As it as been described in patients with chromosomal abnormalities, this form of myoclonic absence like epilepsy in HHS patients tends to be refractory to antiepileptic drugs. [11] [12] [13] In that condition, carbamazepine or its structural relative oxcarbazepine should be avoided since this antiepileptic drugs are known to worsen myoclonic epilepsy as well as absence seizure. Conversely, a combination of levetiracetam, valproic acid and/or zonisamide could proposed with a potential better benefit in seizure control.
There are several possible mechanisms underlying the epilepsy observed in the HI/HA syndrome. It could be a consequence of repeated hypoglycemic events leading to permanent brain injury. It could also be the consequence of chronic hyperammone-662 N. Bahi-Buisson et al. mia even if this has been asymptomatic. Finally, epilepsy could directly result from mutations in the GLUD1 gene leading to an activation of the GDH in brain.
In our family, hypoglycemia cannot solely explain the myoclonic epilepsy as the serum and cerebrospinal fluid glucose levels were normal in the index case during the active phase of the epilepsy and in addition the younger sister and brother were not known to have suffered from hypoglycemic events. Moreover, contrary to cerebral abnormalities seen as a consequence of hypoglycemic events, 14, 15 imaging findings were normal in all our patients and, in particular, they do not show any structural abnormalities previously observed in HI/HA patients (left frontal encephalomalacia, general cerebral atrophy, left frontal porencephalic cyst). 4 This argues against the theory of brain injury or hypoglycemic sequellae.
With regards to the hyperammonemia hypothesis, the hyperammonemia remained asymptomatic and stable in our patients, as demonstrated by the absence of acute neurological symptoms and the absence of mental retardation in the mother. We also observed normal glutamine level in the CSF with no abnormal peak of glutamine detected on MRS. This argues against the theory of brain toxicity secondary to hyperammonemia. Moreover, overactivity of GDH is supposed to protect the central nervous system against some effects of hyperammonemia by preventing excessive accumulation of glutamate and glutamine in brain and maintaining a normal neuronal glutamate pool. 2, 9 The most plausible explanation rests with overactivity of GDH which might alter the concentration of GABA by decreasing brain glutamine and consequently brain GABA. Thus, abnormal concentrations of glutamate and GABA could constitute one putative mechanism of epilepsy in HI/HA syndrome, as shown in myoclonic absence epilepsy secondary to SSADH deficiency. 13 The fact that all our patients described the same pattern of epilepsy provides a plausible explanation for this hypothesis. However, contrary to SSADH deficiency, CSF neurotransmitters were normal.
Finally, the mechanism of this epilepsy could be related to a cerebral K ATP channel dysfunction which is also expressed in the brain. Overactivity of GDH leads to closure of ATP sensitive potassium channels (K ATP ) by increasing ATP/ADP ratio, resulting in sustained neuronal depolarization. Recent reports of an activating mutation in the Kir6.2, subunit of the K ATP channel in DEND syndrome (developmental delay, epilepsy or muscle weakness, neonatal diabetes) also argues for this hypothesis. 16 In DEND syndrome, Kir6.2 mutations cause an increase in whole resting cell K ATP currents by reducing channel inhibition by ATP. This could induce neuronal hyperexcitability and seizures. 17, 18 However, in hyperinsulinemic hypoglycemia in which mutations in SUR1 or Kir6.2 genes are inhibiting mutations leading to close of the channels, epilepsy is rarely described despite severe hypoglycemia. 19 In conclusion, we report one family with a gain of function mutation in GDH with an original phenotype of photosensitive myoclonic absence epilepsy. In this case report, we give new details about the electrophysiological pattern associated with this metabolic disorder and metabolic data that give new insight into the pathophysiological mechanism of this epilepsy.
